KCM
SPRY icon

Kodai Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Kodai Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$756K Buy
+60,111
New +$723K 0.03% 141

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Kodai Capital Management's SPRY Position: Q1 2025 in Review

Kodai Capital Management opened a new position in ARS Pharmaceuticals (SPRY) in Q1 2025: 60,111 shares worth $756K. The stake represents 0.03% of the portfolio and ranks #141 among its holdings.

184 funds tracked by Wall St. Rank hold SPRY as of Q1 2025.

  • Kodai Capital Management held 60,111 shares of ARS Pharmaceuticals worth $756K as of Q1 2025.
  • ARS Pharmaceuticals was a new Kodai Capital Management position in Q1 2025.
  • ARS Pharmaceuticals made up 0.03% of Kodai Capital Management's portfolio in Q1 2025, its #141 holding.
  • 184 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2025.

Based on Kodai Capital Management's 13F filing for Q1 2025, filed 15 May 2025.